ARCH and ACHFF Related Headlines
Go Back- Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
- Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
- Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
- Arch Biopartners raises $600,000 in private placement offering
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners arranges $600,000 private placement at $0.60 per share
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
- Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
- Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
- Arch Biopartners closes $600,000 private placement
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners arranges $500,000 private placement with company officer
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
ARCH and ACHFF Related Press Releases
Go Back- Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
- Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
- Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
- Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
- Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
- Arch Biopartners Closes Non-Brokered Private Placement
- Arch Biopartners Arranges Non-Brokered Private Placement
- Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
